Cleared Special

K201908 - LIAISON Testosterone xt

K201908 is an FDA 510(k) clearance for LIAISON Testosterone xt, manufactured by DiaSorin, Inc.. The device is a Class 1 Chemistry device with product code CDZ cleared through the Special 510(k) pathway after a 98-day FDA review.

K201908 · DiaSorin, Inc. · Chemistry device
Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
Oct 2020
Decision
98d
Days
Class 1
Risk

K201908 is an FDA 510(k) clearance for the LIAISON Testosterone xt. Classified as Radioimmunoassay, Testosterones And Dihydrotestosterone (product code CDZ), Class I - General Controls.

Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on October 15, 2020 after a review of 98 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1680 - the FDA in vitro diagnostics and chemistry framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Standard predicate reliance. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

FDA 510(k) Submission Details - K201908

510(k) Number K201908 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 09, 2020
Decision Date October 15, 2020
Days to Decision 98 days
Submission Type Special
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
9d slower than avg
Panel avg: 89d · This submission: 98d
Pathway characteristics
Modification to existing cleared device.

CDZ Device Classification - Class 1, General Controls

Product Code CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1680
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - CDZ Radioimmunoassay, Testosterones And Dihydrotestosterone

All 84
Devices cleared under the same product code (CDZ) and FDA review panel - the closest regulatory comparables to K201908.
Access SHBG
K233480 · Beckman Coulter, Inc. · Feb 2024
Access Testosterone
K223405 · Beckman Coulter, Inc. · Jan 2023
Elecsys Testosterone II
K211685 · Roche Diagnostics · May 2022
ACTIVE® Free Testosterone RIA
K191350 · Immunotech S.R.O. · Dec 2019
ADVIA Centaur Testosterone II (TSTII), ADVIA Centaur SHBG
K191533 · Siemens Healthcare Diagnostics, Inc. · Aug 2019
IDS SHBG
K190121 · Immunodiagnostic Systems , Ltd. · Jun 2019
K201908 · LIAISON Testosterone xt
Download PDF FDA Summary DiaSorin, Inc.